Pharmacy Times

JUNE 20, 2025

Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? Heidi Finnes, PharmD, BCOP, FHOPA : I shared new hope in cutaneous malignancies and abstracts from the 2025 ASCO meeting. It was approved last year.

Compounding Pharmacies

Pharmacy Times

JUNE 12, 2025

Biologics Versus Biosimilars Biologics Image credit: lexiconimages | stock.adobe.com Darkow begins the presentation by describing biologics as a large, complex molecule that is made of living sources, such as bacteria, yeasts, and animal cells. Unlike other medications and treatments, they are not chemically synthesized.

Immunization

Pharmacy Times

JUNE 23, 2025

Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. If the request doesn’t come in, all 505(b)(2) drugs will be considered nontherapeutically equivalent and therefore get their own J-code. That’s the system we are headed into very rapidly.” REFERENCE Soefje SA.

FDA

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. The Intersection of AI and Pharmacogenetics The integration of AI technologies with pharmacogenetics presents powerful opportunities for enhancing medication therapy management.

Compounding Pharmacies

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 9, 2025

SHOW MORE Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy. The authors wrote that their findings could serve as a baseline for the steroids’ negative independent prognostic factor in patients with NSCLC undergoing ICI therapy.

Immunization

Pharmacy Times

JULY 23, 2025

Pharmacy Times : Can you share what you presented at OPC 2025? Eugene Przespolewski, PharmD, BCOP, DPLA : At OPC, I presented a few different topics, really focused on care models and optimization. So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy.

Specialty Pharmacies

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Participants can present their work, exchange ideas, and connect with leaders in the field during these networking opportunities.

Dosage

Pharmacy Times

JUNE 25, 2025

Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Kevin Chen, PharmD, MS, BCOP, CPP : Yeah, I presented some therapeutic training updates from ASCO for the treatment of thoracic cancers like lung cancer. Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy.

Compounding Pharmacies

Pharmacy Times

JUNE 9, 2025

Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Ukpokpo EE, Cordon M, Luon S, Renauer M.

Compounding Pharmacies

Pharmacy Times

JUNE 27, 2025

I recently had the opportunity to blend my own science and philosophy at the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon, presenting on psychedelic medicines in oncology and palliative care. Fortunately, he had a great oncology team with a pharmacist who specialized in gastrointestinal oncology.

Compounding Pharmacies

Pharmacy Times

JUNE 9, 2025

Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Updated March 20, 2023. Subscribe Now!

Compounding Pharmacies

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Pharmacy Times

JUNE 18, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Results and conclusions will be shared during the OPC presentation. Conclusions Conclusions are pending and will be presented at the OPC meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 18, 2025

They do present novel therapy options and novel combinations, but that doesn't necessarily mean that they're going to lead to the outcomes we're looking for—longer-term outcomes. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy.

Chemotherapy

The Thyroid Pharmacist

AUGUST 1, 2025

Benefits for the Baby Human breast milk is nutrient-rich and contains a variety of anti-inflammatory, immune-protective, and antimicrobial properties that support your baby’s immune system and reduce the risk of lower respiratory tract infections, ear infections (otitis media), and gastroenteritis. What does the research say?

Health and Personal Care Stores

Pharmacy Times

JUNE 25, 2025

These findings, which were published in Heart , are intended to enhance the general awareness of cannabis’s potential to cause cardiovascular harm, particularly in those who present or are at risk for serious cardiovascular disorders. Subscribe Now!

Compounding Pharmacies

Pharmacy Times

JUNE 18, 2025

Results and conclusions will be presented at the 2025 Oncology Pharmacists Connect meeting, promoting innovation and collaboration. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 6, 2025

Additionally, the VPS72 gene was found to be present in extra copies in over half of the evaluated samples, indicating that gains may play a pivotal role in HCC pathogenesis.

Compounding Pharmacies

Pharmacy Times

JUNE 9, 2025

These findings, presented at the 2025 American Society of Clinical Oncology (ASCO) in Chicago, Illinois, aimed to address the unmet need for more effective adjuvant therapies for individuals with completely resected melanoma. Subscribe Now!

Compounding Pharmacies

PharmaShots

JULY 23, 2025

ADCs continue to possess the potential to provide a more impactful benefit to patients than chemotherapy alone, with a more limited toxicity profile. All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. and 30% from China.

Chemotherapy

pharmaphorum

MAY 30, 2022

pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. And once it’s present there, it’s taken up by the cancer cell.

Chemotherapy

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.

Chemotherapy

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

Chemotherapy

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Oral Presentation JGN-75414.

Immunization

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents.

Immunization

Hospital Pharmacy Europe

FEBRUARY 6, 2023

Other recognised causes or insults he mentioned include certain drugs, e.g., some of those used in chemotherapy, as well as both bacterial and fungal infections. In such cases, patients would normally present with shortness of breath. Finally, myocarditis may occur because of systemic infections such as sepsis.

Chemotherapy

pharmaphorum

DECEMBER 21, 2020

Data from trials of the drug wowed ESMO in September – Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies. months, compared with 6.7

Chemotherapy

The Checkup by Singlecare

SEPTEMBER 12, 2023

The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California. This is a typical immunization response as your body builds a defense against possible infection.

Vaccines

European Pharmaceutical Review

DECEMBER 28, 2023

As well as presenting recent findings from the pivotal AFM13-104 study, Andreas also reflects on the challenges encountered and conquered in developing Affimed’s innate cell engager, Acimtamig, which targets CD30 on lymphoma cells and CD16A on NK cells. Can you share some highlights from the data presented at ASH 2023?

Immunization

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

Chemotherapy

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy

Pharmaceutical Technology

SEPTEMBER 13, 2022

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. month progression-free survival (PFS) benefit over SOC chemotherapy. MSI-H/dMMR CRC accounts for 10-15% of all CRC.

Chemotherapy

pharmaphorum

JUNE 8, 2021

At present, innovation resources in most Asian countries and regions have not been translated into a sizeable global market share; neither the world nor the local countries and regions have fully benefited from the innovative activities of biopharmas in this region,” he says. “If Chemotherapy still accounted for 72.6% million in 2030.

Chemotherapy

pharmaphorum

JANUARY 26, 2023

The cancer is particularly challenging for immunotherapy, as it tends to have fewer mutations than other cancers, presenting fewer targets for immune cells, and tends to be immunologically ‘cold’, with few immune cells infiltrating the tumour. It remains ongoing with updated results due in the coming months.

Chemotherapy